Cargando…

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial

BACKGROUND: The Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS/NCT00651456) phase 3 trial demonstrated the superiority of bevacizumab plus pemetrexed–cisplatin triplet over chemotherapy alone in 448 malignant pleural mesothelioma (MPM) patients. Here, we evaluated the prognostic role of Hippo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maille, Elodie, Brosseau, Solenn, Hanoux, Vincent, Creveuil, Christian, Danel, Claire, Bergot, Emmanuel, Scherpereel, Arnaud, Mazières, Julien, Margery, Jacques, Greillier, Laurent, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Molinier, Olivier, Corre, Romain, Monnet, Isabelle, Gounant, Valérie, Langlais, Alexandra, Morin, Franck, Levallet, Guénaëlle, Zalcman, Gérard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461894/ https://www.ncbi.nlm.nih.gov/pubmed/30739911 http://dx.doi.org/10.1038/s41416-019-0379-8

Ejemplares similares

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT‐0701 MAPS phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2022)

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early–stage lung cancer patients from the IFCT-0002 Phase 3 Trial
por: Levallet, Guénaëlle, et al.
Publicado: (2016)

Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
por: Dubois, Fatéméh, et al.
Publicado: (2022)

Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial
por: Dubois, Fatéméh, et al.
Publicado: (2019)

NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells
por: Keller, Maureen, et al.
Publicado: (2019)

RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis—an updated review
por: Dubois, Fatéméh, et al.
Publicado: (2019)

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
por: Gounant, Valérie, et al.
Publicado: (2021)

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
por: Molinier, O., et al.
Publicado: (2021)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy
por: Bergot, Emmanuel, et al.
Publicado: (2013)

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
por: Wislez, Marie, et al.
Publicado: (2022)

Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report
por: Pluvy, Johan, et al.
Publicado: (2019)

The Use of Pro-Angiogenic and/or Pro-Hypoxic miRNAs as Tools to Monitor Patients with Diffuse Gliomas
por: Levallet, Guénaëlle, et al.
Publicado: (2022)

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)
por: Raynaud, C., et al.
Publicado: (2015)

A role for RASSF1A in tunneling nanotube formation between cells through GEFH1/Rab11 pathway control
por: Dubois, Fatéméh, et al.
Publicado: (2018)

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)
por: Couraud, S., et al.
Publicado: (2013)

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
por: Girard, N., et al.
Publicado: (2022)

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
por: Duruisseaux, Michaël, et al.
Publicado: (2017)

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Development and Validation of a Simplified Prognostic Score in SCLC
por: Negre, Elodie, et al.
Publicado: (2020)

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic
por: Girard, N., et al.
Publicado: (2020)

Centrosome, the Newly Identified Passenger through Tunneling Nanotubes, Increases Binucleation and Proliferation Marker in Receiving Cells
por: Dubois, Fatéméh, et al.
Publicado: (2021)

Antiangiogeneic Strategies in Mesothelioma
por: Nowak, Anna K., et al.
Publicado: (2020)

Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study
por: Guezour, Nadia, et al.
Publicado: (2022)

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
por: Bennouna, Jaafar, et al.
Publicado: (2018)

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors
por: Bouchez, Clémentine, et al.
Publicado: (2020)

A new KIF5B–ERBB4 gene fusion in a lung adenocarcinoma patient
por: Guenzi, Edouard, et al.
Publicado: (2021)

Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article
por: Barrière, Jérôme, et al.
Publicado: (2022)

Patients avec cancers thoraciques et COVID-19 : au cœur de la tempête: Patients with chest cancer and COVID-19: at the heart of the storm
por: Gounant, V., et al.
Publicado: (2021)

Investigating Tunneling Nanotubes in Cancer Cells: Guidelines for Structural and Functional Studies through Cell Imaging
por: Dubois, Fatéméh, et al.
Publicado: (2020)

Contribution of the Idylla(TM) System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations
por: Petiteau, Constance, et al.
Publicado: (2021)

A Biphasic and Brain-Region Selective Down-Regulation of Cyclic Adenosine Monophosphate Concentrations Supports Object Recognition in the Rat
por: Hotte, Maïte, et al.
Publicado: (2012)

Professional Exposure to Goats Increases the Risk of Pneumonic-Type Lung Adenocarcinoma: Results of the IFCT-0504-Epidemio Study
por: Lutringer-Magnin, Delphine, et al.
Publicado: (2012)

Effect on eNOS/NO Pathway in MIRI rats with preconditioning of GFPC from Dang Gui Si Ni decoction
por: Qian, Guo-qiang, et al.
Publicado: (2014)

Hypofractionated carbon‐ion radiotherapy for stage I peripheral nonsmall cell lung cancer (GUNMA0701): Prospective phase II study
por: Saitoh, Jun‐ichi, et al.
Publicado: (2019)

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)
por: Vergnenègre, Alain, et al.
Publicado: (2019)

OA07.01. A naturopathic approach to the prevention of cardiovascular disease: a cost effectiveness analysis of a randomized multi-worksite trial
por: Herman, P, et al.
Publicado: (2012)

Optimization of Advanced Live-Cell Imaging through Red/Near-Infrared Dye Labeling and Fluorescence Lifetime-Based Strategies
por: Bénard, Magalie, et al.
Publicado: (2021)

Antimalarial Iron Chelator, FBS0701, Shows Asexual and Gametocyte Plasmodium falciparum Activity and Single Oral Dose Cure in a Murine Malaria Model
por: Ferrer, Patricia, et al.
Publicado: (2012)

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
por: Lambert, Juliette, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1kgrjc4q2t62hdqumhj5udbvi2